Science Raises $400 million Series D to Accelerate PRIMA Availability and Prepare for US Launch

Science has raised a $400 million Series D with participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech, among others. The capital will accelerate PRIMA’s availability across Europe, prepare for its United States launch and support infrastructure and biohybrid program investments.
- Raised
- $400 million
- Round
- Series D
- Investors
- 6
- Investors
- Khosla VenturesAckman Oxman InstituteTenet Healthcare885 CapitalY CombinatorPLC Neurotech
- Target market
- Patients blinded by certain types of late-stage macular degeneration
- Use of funds
- Accelerate PRIMA’s availability across Europe, prepare for its United States launch, expand research, manufacturing and operational infrastructure, and make substantial further investments in the biohybrid program
Get started
Create a free account to read the full story.
Quick Answers
What is the latest news about Science?
Science has raised a $400 million Series D with participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech, among others. The capital will accelerate PRIMA’s availability across Europe, prepare for its United States launch and support infrastructure and biohybrid program investments.
What does Science do?
Founded in 2021, Science develops neural interfaces, including PRIMA for patients blinded by certain types of late-stage macular degeneration and a biohybrid program combining engineered neurons with the brain’s circuits.
How much did Science raise?
Science raised $400 million in its Series D.
Who invested in Science?
Investors named in this Series D include Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech.
How will Science use the funding?
Science plans to use the money for accelerate PRIMA’s availability across Europe, prepare for its United States launch, expand research, manufacturing and operational infrastructure, and make substantial further investments in the biohybrid program.
Who are the key people at Science?
Key people named in this report: Max Hodak (Co-Founder and CEO).
